Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.

Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine.Thirty-one adults, 18-55 years, 20 naive and 11 prior rAd5 vaccine recipi...

Full description

Bibliographic Details
Main Authors: Uzma N Sarwar, Laura Novik, Mary E Enama, Sarah A Plummer, Richard A Koup, Martha C Nason, Robert T Bailer, Adrian B McDermott, Mario Roederer, John R Mascola, Julie E Ledgerwood, Barney S Graham, VRC 015 study team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4179264?pdf=render

Internet

http://europepmc.org/articles/PMC4179264?pdf=render

Similar Items